Entrada Therapeutics holder sells 62,714 shares

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) had affiliated investment entities associated with MPM BioVentures, including MPM BioVentures 2018, L.P., a ten percent owner, report open-market sales of an aggregate 62,714 shares of common stock over three days at weighted average prices around the reported per-share figures. The sales were made indirectly through several MPM BioVentures and related LLC and limited partnership vehicles, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest.

Insider Trade Summary

Net Seller: 62,714 shares

Net Sell 3 txns

Insider MPM BIOVENTURES 2018, L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC

Role 10% Owner | 10% Owner | 10% Owner

Sold 62,714 shs ($462K)

Type	Security	Shares	Price	Value
Sale	Common Stock F8, F9, F4, F10	14,569	$7.06	$103K
Sale	Common Stock F5, F6, F4, F7	26,522	$7.54	$200K
Sale	Common Stock F1, F2, F3, F4	21,623	$7.34	$159K

Holdings After Transaction: Common Stock — 4,318,348 shares (Indirect, See Footnote)

Footnotes (10)

1. F1. The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. F3. The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.
4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. F5. The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.
6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. F7. The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.
8. F8. The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.
9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. F10. The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.

Key Figures

Shares sold on 2026-08-24: 21,623 shares of Common Stock at $7.3400 per share Shares sold on 2026-08-25: 26,522 shares of Common Stock at $7.5400 per share Shares sold on 2026-08-26: 14,569 shares of Common Stock at $7.0600 per share +3 more

6 metrics

Shares sold on 2026-08-24 21,623 shares of Common Stock at $7.3400 per share Open-market sale reported as an indirect transaction

Shares sold on 2026-08-25 26,522 shares of Common Stock at $7.5400 per share Open-market sale reported as an indirect transaction

Shares sold on 2026-08-26 14,569 shares of Common Stock at $7.0600 per share Open-market sale reported as an indirect transaction

Total shares sold 62,714 shares of Common Stock Aggregate net shares sold across the three reported transactions

Post-transaction holdings BV 2014 1,960,891 shares Shares of TRDA common stock held by BV 2014 after August 26, 2026 sale

Post-transaction holdings BV 2018 2,012,494 shares Shares of TRDA common stock held by BV 2018 after August 26, 2026 sale

Key Terms

weighted average sale price, pecuniary interest, beneficial ownership, ten percent owner

4 terms

weighted average sale price financial

"Price represents the weighted average sale price of the shares sold."

pecuniary interest financial

"disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest"

beneficial ownership financial

"Each Reporting Person disclaims beneficial ownership of the securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

ten percent owner regulatory

"reporting persons are indicated as ten percent owners of the issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who reported the insider transactions in TRDA on this Form 4?

The reported transactions in TRDA involve MPM BIOVENTURES 2018, L.P., MPM BioVentures 2018 LLC, and MPM BioVentures 2018 GP LLC, which are identified as ten percent owners of Entrada Therapeutics, Inc. The trades were executed through affiliated MPM BioVentures funds and entities.

How many Entrada Therapeutics (TRDA) shares were sold in these insider transactions?

Affiliated MPM BioVentures entities reported selling a total of 62,714 shares of Entrada Therapeutics common stock, consisting of 21,623 shares on August 24, 26,522 shares on August 25, and 14,569 shares on August 26, 2026, all as indirect holdings.

At what prices were the TRDA shares sold by the MPM BioVentures affiliates?

The reported per-share prices were $7.3400 for 21,623 shares on August 24, $7.5400 for 26,522 shares on August 25, and $7.0600 for 14,569 shares on August 26, 2026. Footnotes state these are weighted average sale prices within specified intraday price ranges.

Were the TRDA insider sales made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked as true, and the footnotes describing the sales and holdings do not state that the transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

How are the TRDA shares held across the MPM BioVentures entities after these sales?

Following the August 26, 2026 sales, the footnotes state the shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B), and 39,719 by AM BV2018.

Do the reporting persons claim full beneficial ownership of the TRDA shares?

No. A footnote states that each reporting person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest in them, indicating the holdings are largely through funds and managed entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 09:28 PM EDT Accepted by SEC EDGAR 08/26/2026 - 09:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MPM BIOVENTURES 2018, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/24/2026		S		21,623(1)	D	$7.34(2)	4,359,439	I	See Footnote(3)(4)
Common Stock	08/25/2026		S		26,522(5)	D	$7.54(6)	4,332,917	I	See Footnote(4)(7)
Common Stock	08/26/2026		S		14,569(8)	D	$7.06(9)	4,318,348	I	See Footnote(4)(10)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

MPM BIOVENTURES 2018, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM BioVentures 2018 LLC

(Last) (First) (Middle)

C/O MPM CAPITAL BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM BioVentures 2018 GP LLC

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. ("BV 2014"), 655 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 338 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 10,077 by MPM BioVentures 2018, L.P. ("BV 2018"), 535 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 199 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018.

4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

5. The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018.

6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

7. The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018.

8. The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018.

9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

10. The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018.

Remarks:

See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.

	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P.	08/26/2026
	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC	08/26/2026
	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)